Point-of-Care HIV Testing and Early Dolutegravir Use for Infants
Point-of-Care HIV Testing and Early Dolutegravir Use for Infants
This study is being conducted to explore the feasibility of implementing targeted birth HIV testing of high-risk neonates using facility-based point-of-care (POC) HIV diagnostics, and to improve the ability to implement the best standard-of-care treatment possible. Infants found to be HIV infected will be immediately offered enrollment into a dolutegravir (DTG) antiretroviral treatment study cohort (if maternal consent is granted) or referred for treatment at a government facility. Infants who enter the study treatment cohort will be prospectively followed through 96 weeks of age. ART will follow Botswana guidelines.
Inclusion criteria for point-of-care infant HIV testing:
<12 weeks of ART prior to delivery (including no ART); Known HIV-1 viremia (above level of detection) for last test performed or at any time >24 weeks gestation in pregnancy; CD4 cell count known to be <350 cells/mm3 within the past year; Self-described poor adherence in pregnancy (1 or more complete days of missed ART)
Exclusion criteria for point-of-care infant HIV testing:
1) Medical condition making it unlikely that the infant will survive to 24 months
Inclusion criteria for infant longitudinal treatment cohort:
Exclusion criteria for infant longitudinal treatment cohort: